http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104188912-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 |
| filingDate | 2014-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104188912-B |
| titleOfInvention | Tadalafei solid dispersions and its tablet |
| abstract | The invention discloses a kind of preparation method of Tadalafei solid dispersions：Tadalafei and carrier material are dissolved in absolute ethyl alcohol, 50~90 DEG C of decompression rotary evaporations, produced；The mass ratio of the Tadalafei and carrier material is 1:0.5~1:13；The carrier material is selected from one or both of PVP K30, poloxamer.Present invention also offers a kind of Tadalafei solid dispersions tablet：It is made up of Tadalafei solid dispersions, filler, disintegrant, lubricant, wherein, filler loading accounts for the 40%~70% of total weight of tablet；Disintegrant dosage accounts for the 0.5%~10% of total weight of tablet；Lubricant quantity accounts for the 0.1%~5% of total weight of tablet.The Tadalafei solid dispersions of the present invention, and tablet, improve the dissolution in vitro of Tadalafei, improve the shortcomings that its oral absorption is poor, bioavilability is low. |
| priorityDate | 2014-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.